Research summary

TRIUMPH-1 enrolled 2,339 adults without type 2 diabetes who had obesity or overweight with a weight-related condition and followed weekly retatrutide for 80 weeks. At 12 mg, mean weight loss was 28.3% under the efficacy estimand and 25.0% under the treatment-regimen estimand (NEJM report).

Retatrutide remains investigational in the article’s evidence framing.

Summary revised November 1, 2026. This editorial update does not constitute a new literature review.

What Is Retatrutide?

Retatrutide (development code LY-3437943) is Eli Lilly’s investigational obesity and type 2 diabetes peptide: a single engineered peptide designed for once-weekly subcutaneous use that activates three hormone receptors at the same time — GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Researchers usually shorten the name to “reta” or “reta peptide,” and some UAE suppliers market it as “GLP-3” (or “GLP3”) — a misnomer, since there is no GLP-3 receptor and retatrutide acts on the GLP-1, GIP, and glucagon receptors. The GLP-3 retatrutide naming guide decodes these seller labels. None of them is a brand name: Lilly has not announced one for the investigational molecule. In practical terms, retatrutide targets the receptor systems that help regulate hunger, blood sugar, and energy expenditure, which is why it sits at the centre of current interest in newer triple agonist drugs for metabolic disease research. Unlike CagriSema, a fixed-dose combination of two separate molecules (cagrilintide and semaglutide), retatrutide works through one molecule that binds and activates all three targets at once:

Dosing is once-weekly subcutaneous, matching the administration pattern of semaglutide and tirzepatide. Phase 2 tested 1, 4, 8, and 12 mg weekly maintenance doses. If approved, retatrutide would become the first triple agonist on market and Eli Lilly’s next-generation successor to tirzepatide. For regulatory tracking, see Is retatrutide approved?

Evidence and context

Retatrutide (LY-3437943) is Eli Lilly’s investigational once-weekly subcutaneous peptide that activates three receptors in a single molecule: GLP-1, GIP, and glucagon. In the pivotal Phase 3 TRIUMPH-1 trial (topline May 21, 2026, n=2,339, no T2D), retatrutide produced 28.3% mean weight loss at 80 weeks on 12 mg (efficacy estimand; the NEJM paper of September 29, 2026 reports 25.0% under the treatment-regimen estimand), rising to 30.3% (~85.0 lb) at 104 weeks in a BMI ≥35 extension — the deepest weight loss reported for any obesity candidate to date. The Phase 2 NEJM dataset (~24.2% at 48 weeks) remains the historical anchor. Retatrutide is not yet approved in any territory. TRIUMPH-2 (T2D, up to 20.8%) and TRIUMPH-3 (severe obesity with established CVD, up to 22.6%) reported positive results on July 23, 2026, and Lilly plans to submit retatrutide for US approval in Q1 2027. For the compound-level route through trials, approval status, dosing, Dubai availability, and comparisons, use the retatrutide research hub.

Additional context

Mechanism of Action

The retatrutide hypothesis is that the three receptor arms are mechanistically complementary, not redundant. Each arm addresses a different component of body-weight regulation:

Compared to the obesity-pipeline alternatives, retatrutide is the only late-stage candidate that targets energy expenditure in addition to appetite. Tirzepatide is a dual agonist, while semaglutide works mainly through appetite and satiety, so triple-agonist designs may drive more weight loss and help some people lose weight when older weight loss drugs fall short. That broader mechanism is also why researchers ask how does retatrutide work to treat obesity and metabolic disease. Survodutide targets GLP-1 and glucagon (skipping GIP). CagriSema targets GLP-1 and amylin (skipping GIP and glucagon). Retatrutide is the mechanistic superset. For a receptor-by-receptor breakdown of what each arm controls and what trials measure, see the GLP-1, GIP and glucagon mechanism of action page.

Development Stage & TRIUMPH Programme

Retatrutide is in Phase 3 across the TRIUMPH programme, now broadened well beyond the original four lead indications — current Phase 3 work spans obesity, type 2 diabetes, knee osteoarthritis, moderate-severe obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and MASLD/MASH. Cumulative TRIUMPH enrolment exceeds 5,800. The pivotal TRIUMPH-1 obesity trial reported topline results on May 21, 2026 — 28.3% mean weight loss at 80 weeks on 12 mg (n=2,339), rising to 30.3% (~85.0 lb) at 104 weeks in a BMI ≥35 extension — joining the earlier TRIUMPH-4 readout (Dec 2025) and the TRANSCEND-T2D-1 readout (Mar 2026). Detailed TRIUMPH-1 results were presented at the 86th ADA Scientific Sessions in June 2026. TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) reported positive topline results on July 23, 2026, and Lilly now cites five positive Phase 3 studies. Lilly plans to submit retatrutide for US approval in Q1 2027 (Lilly release). TRIUMPH-5, TRIUMPH-6 and TRIUMPH-Outcomes continue. Lilly’s pre-approval expanded-access record on ClinicalTrials.gov (NCT07629401, status “Available”) was first posted in June 2026 and last updated in August 2026.

Trial Population Design Primary readout
TRIUMPH-1 Adults with obesity Placebo-controlled, 80+ weeks Reported May 2026 — 28.3% at 80 weeks (12 mg)
TRIUMPH-2 Obesity + type 2 diabetes Placebo-controlled Reported July 23, 2026 — up to 20.8% at 80 weeks (12 mg) vs 4.0% placebo
TRIUMPH-3 Severe obesity + established cardiovascular disease Placebo-controlled weight trial (not a CVOT) Reported July 23, 2026 — up to 22.6% at 80 weeks (12 mg) vs 3.2% placebo
TRIUMPH-4 Obesity + knee osteoarthritis Function + weight loss Reported Dec 2025 — 28.7% weight loss

Regulatory outlook: TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 have all reported. TRIUMPH-2 (T2D, 80 weeks) showed 12.7% / 19.1% / 20.8% weight loss at 4 / 9 / 12 mg vs 4.0% placebo, with A1C reductions of up to 1.6 points (efficacy estimand); its full results were published in The Lancet on September 29, 2026, where the treatment-regimen estimand gave −11.9% / −16.8% / −18.8% vs −5.1% placebo. TRIUMPH-3 (severe obesity with established CVD, 80 weeks) showed 21.6% / 22.6% at 9 / 12 mg vs 3.2%; its MACE-5 hazard ratio was 0.82 (95% CI 0.55–1.22), and the trial was not powered for cardiovascular outcomes. The next gating milestone is Lilly’s planned US filing in Q1 2027. Whether retatrutide is regulated as a drug or a biologic is before the Seventh Circuit; see Is Retatrutide a Peptide or a Biologic?. A readout from the dedicated outcomes trial, TRIUMPH-Outcomes, would strengthen label positioning versus approved competitors. Retatrutide is not approved anywhere as of October 12, 2026. For a running timeline, see the TRIUMPH trial tracker and the broader obesity drug pipeline timeline.

Manufacturing & commercial outlook: Following the TRIUMPH-1 readout, a Lilly executive said (May 21, 2026) the company hopes to launch the drug around 2027, with an FDA submission expected in 2026. On July 23, 2026, Lilly updated this guidance: it now plans to file for US approval in Q1 2027. Separately, Lilly’s $4.5 billion additional Indiana manufacturing investment (announced May 6, 2026) expands capacity that supports its obesity and incretin pipeline — the same pipeline that includes retatrutide — rather than naming any single molecule. Sources: CNBC, PR Newswire.

Efficacy Data — TRIUMPH-1 Pivotal Phase 3 (May 2026)

The pivotal Phase 3 dataset is TRIUMPH-1 — a randomised, double-blind, placebo-controlled trial in 2,339 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidity), excluding T2D. Baseline mean BMI 40.0; baseline weight 112.7 kg. Eli Lilly reported positive topline results on May 21, 2026. All three doses met the primary and key secondary endpoints.

Dose Mean weight loss at 80 wks Absolute weight loss
Placebo −2.2% —
4 mg −19.0% 47.2 lb
9 mg −25.9% 64.4 lb
12 mg −28.3% 70.3 lb
12 mg — BMI ≥35 extension (104 wks) −30.3% ~85.0 lb

On the 12 mg dose, 45.3% of participants achieved ≥30% weight loss and 65.3% reached a BMI under 30 — a magnitude often associated with bariatric surgery. A prespecified blinded extension in BMI ≥35 completers, maintained on 12 mg to the maximum tolerated dose, showed continued reduction to 30.3% mean weight loss at 104 weeks without an apparent plateau. Cardiometabolic improvements accompanied the weight loss, including a 24.1 cm waist-circumference reduction and favourable changes in non-HDL cholesterol, triglycerides, systolic blood pressure, and hs-CRP. Detailed results were presented at the 86th ADA Scientific Sessions in June 2026. Sources: Lilly investor release, TCTMD, AJMC.

Efficacy Data — Phase 2 NEJM Trial (Historical Context)

The Phase 2 dataset anchoring retatrutide’s pre-Phase-3 positioning is the 48-week randomised, double-blind, placebo-controlled trial published by Jastreboff and colleagues in the New England Journal of Medicine (June 2023). The trial enrolled 338 adults with obesity without type 2 diabetes and tested four retatrutide doses (1, 4, 8, 12 mg) against placebo.

Dose Mean weight change ≥15% weight loss
Placebo −2.1% Minimal
1 mg −8.7% —
4 mg −17.1% —
8 mg −22.8% —
12 mg −24.2% 83% of participants

Two features of the Phase 2 readout shaped retatrutide’s Phase 3 positioning. First, the dose-response was steep and orderly — every dose step produced meaningfully greater weight loss, which is a strong signal that the mechanism is active at the receptor level. Second, the 12 mg weight-loss curve had not plateaued at 48 weeks, implying longer dosing windows (as in TRIUMPH) could push efficacy higher still.

For cross-class context, semaglutide 2.4 mg produced ~15% weight loss at 68 weeks in STEP 1, and tirzepatide 15 mg produced ~22.5% at 72 weeks in SURMOUNT-1. Retatrutide’s 48-week number exceeds both, and the triple-agonist architecture provides a plausible mechanism. For a three-way breakdown, see Retatrutide vs Tirzepatide vs CagriSema.

May 2026 Research Update — Metabolomic Signature

A Phase 2 sub-study in JCEM (Pearson et al, May 14, 2026) profiled plasma metabolomics and lipidomics in 282 participants with obesity and 213 with type 2 diabetes. Higher retatrutide doses drove a coordinated rise in fatty-acid oxidation markers — 3-hydroxybutyrate, acetylcarnitine, and long-chain acylcarnitines — that mediated 23.2% of the weight-reduction response in the obesity arm versus only 12.7% in the T2D arm. Branched-chain amino acids, 2-aminoadipic acid, and urate — all insulin-resistance markers — fell across both populations, alongside a reduction in triglycerides enriched for short-chain and saturated acyl chains. The signal suggests retatrutide changes how weight is lost, not just how much, with measurably different metabolic mediation in obesity-only versus obesity-plus-diabetes.

Safety & Tolerability

Retatrutide’s Phase 2 safety profile was consistent with the GLP-1 class, layered with glucagon-related signals requiring further characterisation in Phase 3:

No unexpected safety signals were reported in Phase 2. Long-term tolerability, cardiovascular outcomes, and discontinuation rates at commercial-intent doses are being characterised in TRIUMPH. For a dose-by-dose breakdown, see Phase 3 safety & adverse-event rates below. For a broader checklist of HbA1c, CMP, lipid, thyroid, and pancreatic-risk labs used before GLP-1-class protocols, see blood tests before starting GLP-1s and peptides.

Phase 3 Safety & Adverse-Event Rates

The Phase 2 dataset (Jastreboff et al., NEJM 2023) and the Phase 3 TRIUMPH-1 (May 2026), TRIUMPH-4 (December 2025), and TRANSCEND-T2D-1 (March 2026) topline readouts together form the most comprehensive safety dataset for retatrutide to date. The composite picture is consistent: gastrointestinal events dominate, severity is mostly mild-to-moderate, discontinuation runs in the single digits to low double digits at the highest dose, and titration design is the strongest tolerability lever.

TRIUMPH-1 dose-by-dose tolerability (May 21, 2026)

Endpoint 4 mg 9 mg 12 mg Placebo
AE-driven discontinuation 4.1% 6.9% 11.3% 4.9%
Dysesthesia — up to 12.5% —
Urinary tract infections 7.5% / 8.8% / 8.4% across 4 / 9 / 12 mg vs 5.3% placebo
Adverse events — most common Gastrointestinal (nausea, diarrhea, vomiting, decreased appetite); concentrated in dose-escalation window

The TRIUMPH-1 dose-dependent discontinuation curve (4.1% / 6.9% / 11.3% vs 4.9% on placebo) is below the 18.2% AE-driven discontinuation at 12 mg in TRIUMPH-4 (obesity plus knee osteoarthritis), which Lilly says used the same escalation scheme; the two populations differ. Dysesthesia at 12.5% sits between the TRIUMPH-4 high-dose signal and the lower TRANSCEND-T2D-1 incidence (2.3–4.5%). The new UTI signal is the most notable late-emerging observation and was quantified in Lilly’s release at 7.5–8.8% across retatrutide groups versus 5.3% on placebo. Detailed results were presented at the 86th ADA Scientific Sessions in June 2026.

TRIUMPH-1 vs TRIUMPH-4 — tolerability at the 12 mg dose

The clearest read on retatrutide’s evolving tolerability is the side-by-side comparison of the two high-dose obesity readouts. The pivotal TRIUMPH-1 obesity cohort showed lower rates than TRIUMPH-4 (obesity plus knee osteoarthritis) on both the dysesthesia signal and AE-driven discontinuation.

Endpoint (12 mg) TRIUMPH-1 (obesity, no T2D) TRIUMPH-4 (obesity + knee OA)
Dysesthesia 12.5% 20.9%
AE-driven discontinuation 11.3% 18.2%

Both the dysesthesia rate (12.5% vs 20.9%) and AE-driven discontinuation (11.3% vs 18.2%) ran lower in TRIUMPH-1 than in TRIUMPH-4, Lilly reports the same escalation scheme in both trials, so the difference more likely reflects the populations (TRIUMPH-4 enrolled people with knee osteoarthritis, 84% with a baseline BMI of 35 or more). Sources: Lilly’s TRIUMPH-4 release (December 11, 2025) and TRIUMPH-1 release (May 21, 2026).

Phase 2 GI rates by dose & titration design

Dose Cohort Titration Design Nausea Diarrhea Vomiting Constipation
Placebo (N=70) — 11% 11% 1% 3%
1 mg (N=69) No escalation 14% 9% 3% 7%
4 mg (N=33) Slow (2→4 mg) 18% 12% 12% 15%
4 mg (N=33) Rapid (start at 4 mg) 36% 12% 12% 6%
8 mg (N=35) Slow (2→4→8 mg) 17% 20% 6% 11%
8 mg (N=35) Rapid (start at 4 mg) 60% 20% 26% 11%
12 mg (N=62) Slow (2→4→8→12 mg) 45% 15% 19% 16%

Key finding: The 8 mg rapid-start cohort produced higher nausea (60%) than the 12 mg slow-titration cohort (45%), even though the final dose was lower. Nausea incidence is dose dependent, but the starting dose mattered: a 2 mg start halved nausea at 4 mg (18% vs 36%) and cut it from 60% to 17% at 8 mg. Phase 2 used four-week dose-escalation steps to allow adaptation during the treatment period (Jastreboff et al., NEJM 2023, Table 3).

Cross-class comparison — retatrutide vs tirzepatide vs semaglutide

Side Effect Retatrutide (12 mg) Tirzepatide (15 mg) Semaglutide (2.4 mg) Placebo (retatrutide Phase 2)
Nausea 45% 31.0% 44.2% 11%
Diarrhea 15% 23.0% 31.5% 11%
Vomiting 19% 12.2% 24.8% 1%
Constipation 16% 11.7% 23.4% 3%
Discontinuation (AE) 16% (12 mg; 6–16% across arms) 4.3–7.1% across doses 7.0% 0%

Retatrutide’s Phase 2 GI rates (NEJM 2023, Table 3; tirzepatide 15 mg figures from Lilly’s April 28, 2022 SURMOUNT-1 release; semaglutide 2.4 mg figures from the STEP 1 trial, NEJM 2021) sit in the same general range as tirzepatide and semaglutide, though nausea peaked at 60% in the 8 mg arm started at 4 mg. Phase 2 AE-driven discontinuation (6–16% by arm) ran above the SURMOUNT-1 range at the highest doses. Populations, durations and escalation schemes differ, so cross-trial comparisons are directional only.

Severity stratification

Phase 2 trial reports describe retatrutide adverse events as predominantly mild-to-moderate, with severe events under 5% per individual AE category. AE-driven discontinuation was 6–16% across the Phase 2 retatrutide arms (7%, 6%, 9%, 14%, 6% and 16% by arm) vs 0% on placebo, and 2.2–5.1% across TRANSCEND-T2D-1 dose arms.

Adverse Event % Mild % Moderate % Severe % Leading to Discontinuation
Nausea Majority mild Minority moderate <5% reported 6–16% by Phase 2 arm (AE-driven discontinuation, all causes)
Diarrhea Majority mild Minority moderate <5% reported 6–16% by Phase 2 arm (AE-driven discontinuation, all causes)
Vomiting Majority mild-to-moderate Minority moderate <5% reported 6–16% by Phase 2 arm (AE-driven discontinuation, all causes)
Constipation Majority mild Minority moderate Rare Trial-reported as low
Dysesthesia Majority mild-to-moderate Minority moderate Rare per TRIUMPH-4 Trial-reported as low
Injection-site reactions Majority mild Minority moderate Rare Trial-reported as low

GI symptom timeline — onset, peak, resolution

Trial narrative reports describe a consistent onset/peak/resolution pattern for the GI category, with most events concentrated in the dose-escalation window.

Adverse Event Onset (Week 1–2) Peak (Week 2–4) Resolution (Week 4–8)
Nausea Within first 1–2 weeks of new dose level Peaks during weeks 2–4 of titration Tolerance develops with continued dosing; generally resolves by week 4–8
Diarrhea Within first 1–2 weeks of new dose level Peaks during weeks 2–4 of titration Predominantly transient and self-limiting
Vomiting Most events during initial titration period Peaks during weeks 2–4 of titration Diminishes as participants reach maintenance dose
Dysesthesia Trial-reported timing not stratified by week Trial-reported timing not stratified by week TRANSCEND-T2D-1 narrative: generally mild, with most resolving during treatment
Injection-site reactions May appear within 24–72h post-dose Transient Self-limiting in most cases (24–48h without intervention)

Severe abdominal pain was reported in a small subset of Phase 2 participants at higher doses. Trial reports describe pain that persists beyond 48 hours or is accompanied by persistent vomiting as a flag for further investigation, with acute pancreatitis included in the differential and pancreatic enzymes (serum amylase, lipase) measured to rule out acute pancreatic disorders. The Phase 2 trial reported one adjudicated case of acute pancreatitis among 267 retatrutide participants (none among 70 on placebo), and the GLP-1 class warning applies by mechanism.

TRIUMPH-4 Phase 3 update (December 2025)

Eli Lilly reported topline results from the TRIUMPH-4 Phase 3 trial on December 11, 2025. TRIUMPH-4 evaluated retatrutide in adults with obesity and knee osteoarthritis across a larger and more diverse population than Phase 2, using the Phase 3 escalation scheme informed by Phase 2 dose-finding. Topline results confirmed that retatrutide met its primary efficacy endpoints. Lilly reported AE-driven discontinuation of 12.2% at 9 mg and 18.2% at 12 mg vs 4.0% on placebo, and dysesthesia — tingling/numbness — in 8.8% and 20.9% vs 0.7% on placebo. No peer-reviewed TRIUMPH-4 report had appeared in PubMed as of October 12, 2026.

TRANSCEND-T2D-1 Phase 3 readout (March 2026)

On March 19, 2026, Eli Lilly announced topline results from TRANSCEND-T2D-1 — the first Phase 3 trial evaluating retatrutide in type 2 diabetes. The 40-week, placebo-controlled study randomised 537 participants to retatrutide 4 mg, 9 mg, or 12 mg (starting at 2 mg with four-week dose escalation) or placebo.

Adverse Event 4 mg 9 mg 12 mg Placebo
Nausea 16.4% 19.5% 26.5% 3.7%
Diarrhea 18.7% 26.3% 22.8% 4.5%
Vomiting 15.7% 15.0% 17.6% 2.2%
Dysesthesia 4.5% 2.3% 4.4% 0%
Discontinuation (AE) 2.2% 4.5% 5.1% 0%

Notably, nausea rates in TRANSCEND-T2D-1 (16.4–26.5%) ran lower than in the Phase 2 obesity trial (45% at 12 mg, up to 60% in the 8 mg arm started at 4 mg); the populations differ, and the Phase 2 12 mg arm also started at 2 mg. Dysesthesia — the tingling/numbness signal first flagged in TRIUMPH-4 — occurred in 2.3–4.5% of retatrutide-treated participants and was described as generally mild, with most resolving during treatment. Discontinuation rates due to adverse events were low across all doses (2.2–5.1%). Detailed TRANSCEND-T2D-1 safety results were presented at the American Diabetes Association Scientific Sessions in June 2026.

Heart rate & cardiovascular signals

The Phase 2 trial reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter (Jastreboff et al., NEJM 2023). Approved GLP-1 receptor agonists such as semaglutide and tirzepatide also raise resting heart rate modestly; whether retatrutide’s glucagon arm adds to the effect has not been separately quantified in the published abstracts.

No major adverse cardiovascular events (MACE) were identified as attributable to retatrutide in the Phase 2 trial. No clinically significant arrhythmias, QT prolongation, or blood pressure abnormalities were reported at rates above placebo. Phase 2 was not powered to detect rare cardiovascular events — TRIUMPH-Outcomes is the dedicated cardiovascular outcomes trial that will provide definitive long-term CV safety data; the 80-week TRIUMPH-3 weight trial in people with established CVD was not powered for cardiovascular outcomes.

Class-wide safety considerations

Safety consideration Retatrutide Tirzepatide Semaglutide
Pancreatitis Class warning; no confirmed signal in Phase 2/3 Class warning per FDA label Class warning per FDA label
Gallbladder events Class warning; trial-reported as low Class warning per FDA label Class warning per FDA label
MTC / thyroid C-cell tumors Class warning (rodent data) Boxed warning per FDA label Boxed warning per FDA label
MACE / cardiovascular Pending dedicated CV outcome data (TRIUMPH-Outcomes) SURPASS-CVOT (T2D, vs dulaglutide): non-inferior, MACE-3 HR 0.92. FDA added a MACE-risk-reduction indication to Mounjaro for adults with T2D at high CV risk (August 27, 2026). Obesity outcomes trial SURMOUNT-MMO is ongoing (estimated October 2027). SUSTAIN-6 (T2D) and SELECT (established CVD with obesity or overweight): MACE reduction; CV-risk-reduction indications on Ozempic and Wegovy. (LEADER was a liraglutide trial.)
Suicidal behavior/ideation (FDA) Investigational; no label. FDA’s 2026 class review covered approved GLP-1 receptor agonists only. FDA asked for the suicidal behavior and ideation warning to be removed (Drug Safety Communication, January 13, 2026); the Zepbound label lists it as removed (02/2026). FDA asked for the warning to be removed from the Wegovy label (January 13, 2026) after its review found no increased risk.

Class-wide considerations reference FDA labels for tirzepatide (Mounjaro/Zepbound) and semaglutide (Wegovy/Ozempic). Retatrutide entries reflect investigational status; class warnings apply by mechanism. Combining GLP-1 receptor agonists with insulin or sulfonylureas increases the risk of hypoglycemia — a documented class effect that applies to retatrutide by mechanism. Trial protocols typically reduce concomitant insulin or sulfonylurea doses when GLP-1 agonists are added.

How It Compares — Retatrutide vs Tirzepatide vs CagriSema

Retatrutide sits at the mechanistic top of the obesity pipeline. Tirzepatide (Eli Lilly, approved as Mounjaro and Zepbound) is a dual GLP-1/GIP agonist. CagriSema (Novo Nordisk, NDA filed December 2025) is a fixed-dose combination of cagrilintide and semaglutide (an amylin analogue plus a GLP-1 agonist). Retatrutide adds a glucagon arm that neither of those candidates has, which is the source of its weight-loss ceiling advantage in cross-trial comparison. For the rat-only evidence on pairing retatrutide with cagrilintide, see retatrutide and cagrilintide research.

On efficacy, retatrutide’s Phase 3 TRIUMPH-1 12 mg result (28.3% at 80 weeks; 30.3% at 104 weeks in the BMI ≥35 extension) exceeds tirzepatide 15 mg in SURMOUNT-1 (~22.5% at 72 weeks) and CagriSema in REDEFINE 1 (~22.7% at 68 weeks). Timeline position is inverted: CagriSema is closest to market (Novo guides to a Q4 2026 FDA decision), tirzepatide is already approved, and retatrutide has a US filing planned by Q1 2027. For a full comparative breakdown, see retatrutide vs tirzepatide vs CagriSema, and for orforglipron-specific context, see retatrutide vs orforglipron.

Research Use Notes

Remy Research sells retatrutide pens and vials for in-vitro laboratory research. Janoshik HPLC reports are published for selected batches, including RETP002 for the Remedium Research 30mg FlexiPen (99.262% HPLC); each product page shows its own testing status. Reference the COA library for batch documents. For reconstitution and handling, see the bacteriostatic water guide and the reconstitution calculator.

Retatrutide is not approved for human therapeutic use in any territory. Remy Research material is supplied strictly for in-vitro research. For regional research context, see the Dubai research guide and Retatrutide UAE availability page.

All Remy Research products are supplied for in-vitro laboratory research only. Not for human or veterinary use.

Further reading

Retatrutide (LY-3437943) is Eli Lilly’s investigational once-weekly subcutaneous peptide that functions as a unimolecular triple agonist at the GLP-1, GIP, and glucagon receptors. Unlike combination therapies, retatrutide is a single engineered molecule that simultaneously activates all three pathways. It is the most pharmacologically comprehensive obesity candidate currently in late-stage development.
These are informal names for the same molecule. “Reta” and “reta peptide” are researcher shorthand for retatrutide (LY-3437943). “GLP-3” (or “GLP3”) is a grey-market label some UAE suppliers use — and a misnomer, because there is no GLP-3 receptor. Retatrutide is a triple agonist acting on the GLP-1, GIP, and glucagon receptors; the “GLP-3” name likely tries to signal a third-wave, triple-GLP compound. All of these terms point to retatrutide.
No. Lilly has not announced a brand name for retatrutide (LY-3437943), the generic name of an investigational molecule. It is not approved anywhere, and Lilly has not yet submitted a marketing application; it plans to submit retatrutide for US approval in Q1 2027. Names seen online, such as “GLP-3” or “Reta”, are informal labels, not brand names. Status checked October 12, 2026.
No. As of October 12, 2026, retatrutide is not approved in any regulatory territory. Lilly reported pivotal TRIUMPH-1 (obesity, no T2D) topline on May 21, 2026; TRIUMPH-4 (obesity + knee OA) reported December 2025; TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) reported positive topline results on July 23, 2026. TRIUMPH-2 was published in full in The Lancet on September 29, 2026. Lilly plans to submit retatrutide for US approval in Q1 2027.
In the pivotal Phase 3 TRIUMPH-1 trial (topline May 21, 2026, n=2,339, no T2D), retatrutide 12 mg produced 28.3% mean weight loss (efficacy estimand) at 80 weeks, rising to 30.3% (~85.0 lb) at 104 weeks in a BMI ≥35 extension. 45.3% of 12 mg participants achieved ≥30% weight loss and 65.3% fell below BMI 30. Earlier readouts: TRIUMPH-4 (Dec 2025) reported 28.7% in obesity plus knee osteoarthritis; the Phase 2 trial (Jastreboff et al., NEJM 2023) reported 24.2% at 48 weeks as historical context. Detailed TRIUMPH-1 results were presented at the 86th ADA Scientific Sessions in June 2026.
Retatrutide activates three receptors through a single molecule. GLP-1 receptor activation suppresses appetite and slows gastric emptying, matching the established semaglutide mechanism. GIP receptor activation adds insulinotropic and satiety effects comparable to tirzepatide’s second arm. Glucagon receptor activation is the distinguishing feature, increasing basal energy expenditure and reducing hepatic fat — an arm neither semaglutide nor tirzepatide addresses.
TRIUMPH is Eli Lilly’s Phase 3 clinical programme for retatrutide, spanning four lead trials. TRIUMPH-1 evaluates retatrutide in adults with obesity and without type 2 diabetes. TRIUMPH-2 studies retatrutide in adults with obesity and type 2 diabetes. TRIUMPH-3 evaluates weight loss in adults with severe obesity and established cardiovascular disease; the separate TRIUMPH-Outcomes trial tests cardiovascular and kidney outcomes. TRIUMPH-4 studies retatrutide in adults with obesity and knee osteoarthritis. TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 and TRIUMPH-4 have all reported; Lilly plans to submit retatrutide for US approval in Q1 2027.
Tirzepatide is a dual GLP-1/GIP agonist from the same sponsor (Eli Lilly), already FDA approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Retatrutide adds a third arm — glucagon receptor activation — to tirzepatide’s mechanism. Cross-trial comparisons are limited, but retatrutide’s Phase 2 weight-loss signal (~24% at 48 weeks) exceeds tirzepatide’s SURMOUNT-1 result (~22.5% at 72 weeks), suggesting the glucagon arm adds clinically meaningful efficacy beyond dual-agonism.
Yes. Remy Research sells retatrutide pens and vials for in-vitro laboratory research. Janoshik HPLC reports are published for selected batches, including RETP002 for the Remedium Research 30mg FlexiPen (99.262% HPLC); each product page shows its own testing status. All material is supplied strictly for research use only; not for human or veterinary use.
Gastrointestinal events dominate across all trials. In TRIUMPH-1 Phase 3, AE-driven discontinuation rose with dose: 4.1% on 4 mg, 6.9% on 9 mg, and 11.3% on 12 mg vs 4.9% on placebo. Dysesthesia was reported in up to 12.5% on 12 mg; urinary tract infections were also noted. The Phase 2 dataset (NEJM 2023, Table 3) showed nausea 45%, diarrhea 15%, vomiting 19% and constipation 16% at the 12 mg dose, with nausea peaking at 60% in the 8 mg arm started at 4 mg; events were mild-to-moderate and concentrated in dose escalation. In TRIUMPH-2 (The Lancet, 2026), nausea was reported in 28% on 12 mg vs 8% on placebo. See the Phase 3 safety & adverse-event rates section for the dose-by-dose breakdown.
Dysesthesia — abnormal sensations, often described as tingling — was a notable signal in retatrutide Phase 3 trials. TRIUMPH-1 (May 2026) reported dysesthesia in up to 12.5% of participants on the 12 mg dose; TRIUMPH-4 reported a higher rate at 12 mg (20.9%, vs 8.8% at 9 mg and 0.7% on placebo); TRANSCEND-T2D-1 reported lower single-digit incidence (2.3–4.5%). The mechanism is not fully understood; trial reports describe most cases as transient.
GLP-1 receptor agonists carry a class warning for pancreatitis in their FDA labels. The retatrutide Phase 2 trial reported one adjudicated case of acute pancreatitis among 267 retatrutide participants (none among 70 on placebo), and the molecule’s investigational status means long-term safety data is still accumulating. Severe persistent abdominal pain warrants immediate medical evaluation in any GLP-1 setting.
Combining GLP-1 receptor agonists with insulin or sulfonylureas increases the risk of hypoglycemia. This is a documented effect for the entire GLP-1 class and applies to retatrutide by mechanism. In trial settings, doses of concomitant insulin or sulfonylureas are typically reduced when GLP-1 agonists are added; this is investigational territory for retatrutide and outside any approved-prescribing context.

Our Research Standards

This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews research articles covering GLP-1 receptor agonists, triple agonists, and the obesity drug pipeline. Its review checks sources, numerical claims, scientific and regulatory-status accuracy, and compliance wording.

About the editorial team →
References & Citations
  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. nejm.org
  2. Eli Lilly and Company. Clinical Development Pipeline: retatrutide entries (obesity, OA, OSA; diabetes; CV/renal outcomes; chronic low back pain; metabolic dysfunction-associated steatotic liver disease). Information current as of August 5, 2026. lilly.com
  3. ClinicalTrials.gov. TRIUMPH-1: A Study of Retatrutide (LY-3437943) in Participants With Obesity (NCT05929066). clinicaltrials.gov
  4. ClinicalTrials.gov. TRIUMPH-3: A Study of Retatrutide in Participants With Obesity and Cardiovascular Disease (NCT05882045). clinicaltrials.gov
  5. ClinicalTrials.gov. TRIUMPH-4: A Study of Retatrutide in Participants With Obesity and Osteoarthritis of the Knee (NCT05931367). clinicaltrials.gov
  6. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID 35985340. doi.org/10.1016/j.cmet.2022.07.013
  7. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4). Press release, December 11, 2025. investor.lilly.com
  8. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes (TRANSCEND-T2D-1). Press release, March 19, 2026. investor.lilly.com
  9. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. investor.lilly.com
  10. TCTMD. Retatrutide achieves large weight decreases in patients without diabetes: TRIUMPH-1. May 2026. tctmd.com
  11. AJMC. Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1 trial. May 2026. ajmc.com
  12. U.S. Food and Drug Administration. Drugs@FDA: Mounjaro (tirzepatide), NDA 215866; Zepbound (tirzepatide), NDA 217806; Wegovy (semaglutide), NDA 215256; Ozempic (semaglutide), NDA 209637 — prescribing information and class warnings. Mounjaro · Zepbound · Wegovy · Ozempic
  13. Pearson MJ, Willency JA, Lin Y, et al. Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes. J Clin Endocrinol Metab. 2026 May 14. PMID 42135195. pubmed.ncbi.nlm.nih.gov
  14. Eli Lilly and Company. Lilly to invest an additional $4.5 billion in U.S. manufacturing in Indiana. Press release, May 6, 2026. prnewswire.com
  15. CNBC. Eli Lilly's retatrutide clears its first Phase 3 obesity trial (TRIUMPH-1). May 21, 2026. cnbc.com
  16. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3). Press release, July 23, 2026. investor.lilly.com
  17. ClinicalTrials.gov. TRIUMPH-Outcomes (NCT06383390) and Pre-approval Expanded Access of Retatrutide (NCT07629401). clinicaltrials.gov · clinicaltrials.gov
  18. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169. PMID 42814954. pubmed.ncbi.nlm.nih.gov
  19. U.S. Food and Drug Administration. Mounjaro (tirzepatide) supplement approval letter, S-044/S-045 (MACE-risk-reduction indication, SURPASS-CVOT), August 27, 2026. accessdata.fda.gov
  20. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. PMID 41406444. pubmed.ncbi.nlm.nih.gov
  21. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication, January 13, 2026. fda.gov
  22. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID 37952131. pubmed.ncbi.nlm.nih.gov
  23. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455–1472. Published September 29, 2026. doi:10.1016/S0140-6736(26)01861-1. pubmed.ncbi.nlm.nih.gov
  24. Eli Lilly and Company. Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1. Press release, April 28, 2022. investor.lilly.com
  25. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID 33567185. pubmed.ncbi.nlm.nih.gov